DPP4 inhibitors - Prof. Rayaz Malik - AASD
Darren McGuire | Cardiovascular effects of diabetes medications: Lessons learned from CVOTs
DPP4 inhibitors Januvia and Onglyza for T2 Diabetes are ineffective and dangerous Dr. Alashbal AA
CV Effects of Diabetes Medications: Lessons learned from Cardiovascular Outcomes Trials
Peptide Bioanalysis Webinar
Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist, under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche.
Explore contextually related video stories in a new eye-catching way. Try Combster now!